MU Ionic Solutions Corporation (MUIS), a subsidiary of Mitsubishi Chemical Corporation and UBE Corporation, has entered into a significant patent licensing agreement with Contemporary Amperex Technology Co., Limited (CATL), a global leader in energy storage and electric vehicle battery technologies. The agreement grants CATL access to MUIS’s patented lithium-ion battery (LIB) technologies, particularly in the field of electrolyte innovations.
Enhancing Battery Performance Through Collaboration
MUIS, established in 2020, focuses on the research, production, and global distribution of advanced electrolytes for lithium-ion batteries. Electrolytes are essential components that influence battery safety, performance, and lifespan. MUIS’s proprietary technology is designed to reduce side reactions within the battery, thereby improving power efficiency, extending battery life, and enhancing thermal stability.
By licensing these innovations, CATL aims to integrate MUIS’s cutting-edge electrolyte solutions into its battery systems, allowing for improvements in battery reliability, safety, and performance—particularly important for electric vehicles and renewable energy storage.
Supporting the Growing EV Market
The partnership arrives amid rapid growth in the global electric vehicle (EV) industry, where demand for high-performance, durable, and safe lithium-ion batteries continues to soar. Industry forecasts estimate a nearly 30% annual growth rate for automotive LIBs, driven by the worldwide push toward cleaner energy solutions and carbon neutrality.
Through this agreement, CATL is expected to leverage MUIS’s technologies to enhance its competitive edge in EV battery manufacturing. Meanwhile, MUIS benefits from expanded reach and validation of its proprietary electrolyte solutions in large-scale, real-world applications.
Toward a Sustainable Future
While the financial and technical details of the licensing deal remain confidential, the collaboration marks a strategic milestone for both companies. It exemplifies the power of cross-border partnerships in accelerating technological innovation and meeting the increasing global demand for sustainable energy solutions.
With MUIS’s expertise in electrolyte chemistry and CATL’s leadership in battery manufacturing, the two companies are well-positioned to contribute to the next generation of safer, more efficient lithium-ion batteries—supporting the global transition to electric mobility and renewable energy.
patent
Apple Explores Gesture Recognition with Antenna-Based Object Detection in New Patent Application
The United States Patent and Trademark Office (USPTO) published a new patent application from Apple Inc. that unveils a potential leap in gesture recognition and object interaction technology for future electronic devices. The patent, titled “Electronic Devices with Antennas and VSWR Sensors for Object Detection,” outlines a system that utilizes wireless circuitry, multiple antennas, and Voltage Standing Wave Ratio (VSWR) sensors to detect the position and movement of external objects such as a user’s finger or an Apple Pencil.
The technology, according to the patent documentation, could enable Apple devices to sense the angular location and distance of objects in their vicinity, paving the way for advanced gesture control, adaptive signal direction, and more responsive device interactions — all without requiring traditional cameras or touchscreens.
The Role of VSWR Sensors in Object Detection
VSWR is a measurement typically used in antenna systems to determine impedance mismatches. In Apple’s proposed design, however, VSWR readings are repurposed for spatial sensing. The system measures how signals reflect off nearby objects, with changes in the reflected wave patterns offering clues about the object’s distance and angle relative to the device’s antennas.
By deploying multiple antennas at strategic locations on a device, each equipped with VSWR sensors, the device’s onboard processors can triangulate the position of external elements. For instance, if a user’s finger approaches the side of a tablet or an Apple Pencil hovers above a display, the system can detect this and respond appropriately.
Enhanced Communication and Gesture Recognition
One of the key innovations described in the patent is the device’s ability to adapt its wireless communication dynamically based on the location of nearby objects. If a user’s hand is found to be obstructing the optimal path for signal transmission, the device can automatically adjust beamforming directions or signal power to maintain performance.
More notably, the system opens new possibilities for gesture-based controls. Without relying on cameras or external sensors, a device could recognize finger movements or stylus gestures in the air, offering new ways to navigate interfaces, trigger shortcuts, or interact with content.
Apple suggests that this technology could be integrated into a range of future products, including smartphones, tablets, wearables, and even smart glasses or other head-mounted displays.
Potential Use Cases
The application hints at a number of forward-looking applications for the technology, including:
- Air-based gestures: Users could control volume, scroll through documents, or launch applications with mid-air swipes or circular motions near the device.
- Smart Pencil tracking: Apple Pencil movements could be detected even when not in contact with a screen, improving handwriting and drawing precision or enabling 3D input.
- Adaptive signal optimization: Devices could identify hand positions during use and redirect antennas for better network or accessory connections.
Future Implications
This patent aligns with Apple’s growing interest in spatial computing and non-contact interaction technologies. With products like the Vision Pro and advancements in LiDAR and ultra-wideband (UWB) sensors, Apple continues to push the envelope in how users interact with digital content and hardware.
While not all patents lead directly to commercial products, this filing reinforces Apple’s direction toward intuitive, touch-free user interfaces. It could ultimately influence the next generation of iPads, iPhones, and wearables, further blurring the line between the physical and digital worlds.
As with many of Apple’s patent applications, the timing and implementation of this technology remain uncertain. However, its publication offers a clear glimpse into the company’s ambitions for smarter, more context-aware devices that respond seamlessly to their users’ presence and intent.
Maruti Suzuki e-Vitara Patented in India; Launch Scheduled for September 2025
Maruti Suzuki has officially patented its upcoming electric SUV, the e-Vitara, in India, marking a significant step towards its anticipated launch in September 2025. This move positions Maruti Suzuki to compete in the rapidly expanding electric vehicle (EV) market in India.
Design and Platform
The e-Vitara is built on the Heartect-e platform, a collaboration between Suzuki and Toyota. This platform integrates eAxles, combining the motor and inverter into a single unit, enhancing efficiency and performance. The SUV features a rugged design with elements like 3-point Matrix LED DRLs, rear lamps, 18-inch alloy wheels, and active air vents at the front to improve aerodynamics .
Battery Options and Range
Maruti Suzuki offers two battery pack options, the larger 61 kWh battery is expected to provide a range of over 500 km on a single charge, making it competitive in its segment .
Interior Features
Inside, the e-Vitara boasts a modern cabin with a 10.25-inch instrument cluster, ambient lighting, a floating center console, a wireless charging pad, and a panoramic glass roof. The SUV also offers a 10-way electrically adjustable driver’s seat and a 40:20:40 split rear seat configuration, enhancing comfort and practicality .
Safety and Technology
Safety features include seven airbags as standard across all variants, a 360-degree camera, and a suite of Advanced Driver Assistance Systems (ADAS). These features aim to provide a high level of safety for occupants .
Pricing and Launch Details
The e-Vitara is expected to be priced competitively, with the base 49 kWh variant starting around ₹20 lakh (ex-showroom). The 61 kWh variant could be priced at approximately ₹25 lakh, while the AllGrip-e AWD model may approach ₹30 lakh . Production is set to commence at Maruti’s Gujarat plant, with exports planned to over 100 countries, including Europe and Japan .
Competitors in the Indian Market
Upon launch, the Maruti Suzuki e-Vitara will compete against several established and upcoming electric SUVs in India, including:
Tata Curvv EV: Expected to be priced between ₹17.49 lakh and ₹22.24 lakh .
Mahindra BE 6: Priced at ₹18.90 lakh .
Hyundai Creta Electric: Expected to be priced between ₹17.99 lakh and ₹24.38 lakh .
MG ZS EV: Priced between ₹18.98 lakh and ₹26.64 lakh .
With its competitive pricing, advanced features, and robust performance, the Maruti Suzuki e-Vitara is poised to be a strong contender in the Indian electric SUV market.
Design and Platform
The e-Vitara is built on the Heartect-e platform, a collaboration between Suzuki and Toyota. This platform integrates eAxles, combining the motor and inverter into a single unit, enhancing efficiency and performance. The SUV features a rugged design with elements like 3-point Matrix LED DRLs, rear lamps, 18-inch alloy wheels, and active air vents at the front to improve aerodynamics .
Battery Options and Range
Maruti Suzuki offers two battery pack options, the larger 61 kWh battery is expected to provide a range of over 500 km on a single charge, making it competitive in its segment .
Interior Features
Inside, the e-Vitara boasts a modern cabin with a 10.25-inch instrument cluster, ambient lighting, a floating center console, a wireless charging pad, and a panoramic glass roof. The SUV also offers a 10-way electrically adjustable driver’s seat and a 40:20:40 split rear seat configuration, enhancing comfort and practicality .
Safety and Technology
Safety features include seven airbags as standard across all variants, a 360-degree camera, and a suite of Advanced Driver Assistance Systems (ADAS). These features aim to provide a high level of safety for occupants .
Pricing and Launch Details
The e-Vitara is expected to be priced competitively, with the base 49 kWh variant starting around ₹20 lakh (ex-showroom). The 61 kWh variant could be priced at approximately ₹25 lakh, while the AllGrip-e AWD model may approach ₹30 lakh . Production is set to commence at Maruti’s Gujarat plant, with exports planned to over 100 countries, including Europe and Japan .
Competitors in the Indian Market
Upon launch, the Maruti Suzuki e-Vitara will compete against several established and upcoming electric SUVs in India, including:
Tata Curvv EV: Expected to be priced between ₹17.49 lakh and ₹22.24 lakh .
Mahindra BE 6: Priced at ₹18.90 lakh .
Hyundai Creta Electric: Expected to be priced between ₹17.99 lakh and ₹24.38 lakh .
MG ZS EV: Priced between ₹18.98 lakh and ₹26.64 lakh .
With its competitive pricing, advanced features, and robust performance, the Maruti Suzuki e-Vitara is poised to be a strong contender in the Indian electric SUV market.
Delhi High Court Clarifies Patent Law Standards in Landmark Ruling on Section 3(d) of the Indian Patents Act, 1970
In a landmark judgment, the Delhi High Court has provided critical clarity on the interpretation and application of Section 3(d) of the Indian Patents Act, 1970, particularly in cases concerning pharmaceutical innovations. The decision, rendered in the matter of Ischemix LLC v. The Controller of Patents, emphasizes the standards of patentability and the admissibility of post-filing data in applications involving new forms of known substances.
Section 3(d): A Barrier to Evergreening
Section 3(d) of the Indian Patents Act is a unique provision designed to prevent the “evergreening” of patents—where pharmaceutical companies attempt to extend patent monopolies by making minor modifications to known substances. The provision stipulates that a new form of a known substance is patentable only if it results in a significant enhancement of efficacy. In the context of pharmaceutical inventions, the Supreme Court, in its 2013 ruling in Novartis AG v. Union of India, interpreted “efficacy” to mean “therapeutic efficacy.”
The Ischemix LLC Case: Background
Ischemix LLC filed an appeal against the rejection of its patent application (No. 9739/DELNP/2011) by the Indian Patent Office on the grounds of Section 3(d). The applicant argued that they had submitted robust data—spanning in-vitro, in-vivo, and clinical trial results—along with expert opinions to demonstrate the enhanced therapeutic efficacy of the compound.
The Patent Office, however, rejected the application, noting that while comparative data had been submitted after the oral hearing, the data was not clearly explained or sufficiently correlated to therapeutic enhancement as claimed in the specification.
High Court’s Ruling: Key Takeaways
1. Therapeutic Efficacy as the Benchmark
The Delhi High Court reaffirmed the principle established in Novartis AG v. Union of India—that efficacy in the context of pharmaceutical patents must be understood as therapeutic efficacy. Mere improvements in physicochemical properties like stability or solubility are insufficient unless they translate to demonstrable therapeutic benefits.
2. Comparative Data: A Necessary Requirement
Drawing from its earlier ruling in DS Biopharma Limited v. Controller of Patents, the Court stressed that applicants must furnish comparative efficacy data to demonstrate enhancement over known substances. Importantly, this data should be provided in the form of structured comparative tables and supported by appropriate scientific evidence.
3. Admissibility of Post-Filing Data
The Court recognized the inherent delay in generating empirical efficacy data, especially in the pharmaceutical sector where clinical trials are time-intensive. It ruled that while some indication of efficacy should be included at the time of filing, post-filing data may be considered if it corroborates the technical effects disclosed in the original specification. This position is consistent with the Calcutta High Court’s judgment in Oyster Point Pharma Inc. v. Controller of Patents, which acknowledged the prolonged timeline for drug development.
4. Timing and Explanation of Additional Data
The Court made it clear that post-filing data must be submitted well before the final hearing at the Patent Office and should be clearly explained. Submitting complex efficacy data during written submissions post-hearing without oral explanation could render it ineffective, as the Controller may struggle to appreciate the technical details.
5. Requirement for Correlation with Specification
Referring to AstraZeneca AB v. Intas Pharmaceuticals Ltd., the Court ruled that post-filing data should only confirm technical effects already hinted at or described in the specification. It cannot be used to introduce an entirely new technical effect.
Court’s Direction in Ischemix Case
Recognizing the importance of the data but noting the lack of explanation linking the data to therapeutic efficacy, the Court directed Ischemix LLC to submit an explanatory note correlating the submitted evidence to enhanced efficacy. Upon the Patent Office’s consent, the Court remanded the application for re-examination, thereby allowing a fair opportunity for reconsideration.
Broader Implications for Patent Law
This judgment offers significant guidance to pharmaceutical companies and patent practitioners navigating Section 3(d). It strikes a delicate balance between encouraging genuine innovation and preventing the misuse of the patent system to monopolize marginal improvements. The judgment also reinforces procedural discipline, requiring that critical data be timely, complete, and clearly presented.
Conclusion
The Delhi High Court’s decision in Ischemix LLC v. The Controller of Patents builds upon the jurisprudence laid down in Novartis and contributes to a growing body of case law interpreting Section 3(d). As patent litigation continues to evolve in India’s dynamic pharmaceutical sector, such decisions will serve as important references for determining the scope of patentable subject matter and the treatment of post-filing evidence.
Legal experts expect that the continued engagement of the judiciary with Section 3(d) will bring greater predictability and transparency to India’s patent system, particularly for drug-related inventions.
Section 3(d): A Barrier to Evergreening
Section 3(d) of the Indian Patents Act is a unique provision designed to prevent the “evergreening” of patents—where pharmaceutical companies attempt to extend patent monopolies by making minor modifications to known substances. The provision stipulates that a new form of a known substance is patentable only if it results in a significant enhancement of efficacy. In the context of pharmaceutical inventions, the Supreme Court, in its 2013 ruling in Novartis AG v. Union of India, interpreted “efficacy” to mean “therapeutic efficacy.”
The Ischemix LLC Case: Background
Ischemix LLC filed an appeal against the rejection of its patent application (No. 9739/DELNP/2011) by the Indian Patent Office on the grounds of Section 3(d). The applicant argued that they had submitted robust data—spanning in-vitro, in-vivo, and clinical trial results—along with expert opinions to demonstrate the enhanced therapeutic efficacy of the compound.
The Patent Office, however, rejected the application, noting that while comparative data had been submitted after the oral hearing, the data was not clearly explained or sufficiently correlated to therapeutic enhancement as claimed in the specification.
High Court’s Ruling: Key Takeaways
1. Therapeutic Efficacy as the Benchmark
The Delhi High Court reaffirmed the principle established in Novartis AG v. Union of India—that efficacy in the context of pharmaceutical patents must be understood as therapeutic efficacy. Mere improvements in physicochemical properties like stability or solubility are insufficient unless they translate to demonstrable therapeutic benefits.
2. Comparative Data: A Necessary Requirement
Drawing from its earlier ruling in DS Biopharma Limited v. Controller of Patents, the Court stressed that applicants must furnish comparative efficacy data to demonstrate enhancement over known substances. Importantly, this data should be provided in the form of structured comparative tables and supported by appropriate scientific evidence.
3. Admissibility of Post-Filing Data
The Court recognized the inherent delay in generating empirical efficacy data, especially in the pharmaceutical sector where clinical trials are time-intensive. It ruled that while some indication of efficacy should be included at the time of filing, post-filing data may be considered if it corroborates the technical effects disclosed in the original specification. This position is consistent with the Calcutta High Court’s judgment in Oyster Point Pharma Inc. v. Controller of Patents, which acknowledged the prolonged timeline for drug development.
4. Timing and Explanation of Additional Data
The Court made it clear that post-filing data must be submitted well before the final hearing at the Patent Office and should be clearly explained. Submitting complex efficacy data during written submissions post-hearing without oral explanation could render it ineffective, as the Controller may struggle to appreciate the technical details.
5. Requirement for Correlation with Specification
Referring to AstraZeneca AB v. Intas Pharmaceuticals Ltd., the Court ruled that post-filing data should only confirm technical effects already hinted at or described in the specification. It cannot be used to introduce an entirely new technical effect.
Court’s Direction in Ischemix Case
Recognizing the importance of the data but noting the lack of explanation linking the data to therapeutic efficacy, the Court directed Ischemix LLC to submit an explanatory note correlating the submitted evidence to enhanced efficacy. Upon the Patent Office’s consent, the Court remanded the application for re-examination, thereby allowing a fair opportunity for reconsideration.
Broader Implications for Patent Law
This judgment offers significant guidance to pharmaceutical companies and patent practitioners navigating Section 3(d). It strikes a delicate balance between encouraging genuine innovation and preventing the misuse of the patent system to monopolize marginal improvements. The judgment also reinforces procedural discipline, requiring that critical data be timely, complete, and clearly presented.
Conclusion
The Delhi High Court’s decision in Ischemix LLC v. The Controller of Patents builds upon the jurisprudence laid down in Novartis and contributes to a growing body of case law interpreting Section 3(d). As patent litigation continues to evolve in India’s dynamic pharmaceutical sector, such decisions will serve as important references for determining the scope of patentable subject matter and the treatment of post-filing evidence.
Legal experts expect that the continued engagement of the judiciary with Section 3(d) will bring greater predictability and transparency to India’s patent system, particularly for drug-related inventions.
India Breaks into Top Six Globally in 6G Patent Filings: MoS Telecom
India has achieved a significant milestone in the global race for next-generation wireless technology by ranking among the top six nations in 6G patent filings. This advancement underscores the country’s growing influence in shaping the future of telecommunications.
Strategic Push for 6G Leadership
Under the ‘Bharat 6G Vision,’ India aims to become a leader in the design, development, and deployment of 6G technology by 2030. The government is actively supporting this initiative through various programs, including funding research and development, establishing testbeds, and fostering collaborations between academia and industry. These efforts are expected to contribute to India’s goal of securing a 10% share of global 6G patents and one-sixth of contributions to global standards within the next three years .
Terahertz Frequency Bands: The Heart of 6G Innovation
6G technology is set to revolutionize wireless communication by operating in terahertz (THz) frequency bands, specifically between 95 GHz and 3 THz. This spectrum allows for data rates up to 1 terabit per second, marking a hundredfold increase over 5G speeds. Such capabilities will enable applications like immersive extended reality, digital twins, and seamless integration of terrestrial and non-terrestrial networks .
To facilitate research and development in these high-frequency bands, the Telecom Regulatory Authority of India (TRAI) has recommended setting up experimental authorizations for operations in the THz spectrum. This move is expected to position India as a global hub for 6G R&D .
Collaborative Efforts and Future Outlook
India’s ascent in 6G patent filings is attributed to a combination of government initiatives, private sector investments, and academic collaborations. Telecom giants like Reliance Jio, Bharti Airtel, and Tata Communications are investing heavily in 6G research, establishing research centers, and forming international partnerships to drive innovation .
Looking ahead, India is set to host the World Telecommunications Standardisation Assembly (WTSA) in Delhi from October 14 to 24, 2024.
Conclusion
India’s entry into the top six nations for 6G patent filings signifies a strategic leap towards becoming a global leader in next-generation wireless technology. With continued investment in research, infrastructure, and international collaboration, India is poised to play a pivotal role in defining the future of telecommunications.
Strategic Push for 6G Leadership
Under the ‘Bharat 6G Vision,’ India aims to become a leader in the design, development, and deployment of 6G technology by 2030. The government is actively supporting this initiative through various programs, including funding research and development, establishing testbeds, and fostering collaborations between academia and industry. These efforts are expected to contribute to India’s goal of securing a 10% share of global 6G patents and one-sixth of contributions to global standards within the next three years .
Terahertz Frequency Bands: The Heart of 6G Innovation
6G technology is set to revolutionize wireless communication by operating in terahertz (THz) frequency bands, specifically between 95 GHz and 3 THz. This spectrum allows for data rates up to 1 terabit per second, marking a hundredfold increase over 5G speeds. Such capabilities will enable applications like immersive extended reality, digital twins, and seamless integration of terrestrial and non-terrestrial networks .
To facilitate research and development in these high-frequency bands, the Telecom Regulatory Authority of India (TRAI) has recommended setting up experimental authorizations for operations in the THz spectrum. This move is expected to position India as a global hub for 6G R&D .
Collaborative Efforts and Future Outlook
India’s ascent in 6G patent filings is attributed to a combination of government initiatives, private sector investments, and academic collaborations. Telecom giants like Reliance Jio, Bharti Airtel, and Tata Communications are investing heavily in 6G research, establishing research centers, and forming international partnerships to drive innovation .
Looking ahead, India is set to host the World Telecommunications Standardisation Assembly (WTSA) in Delhi from October 14 to 24, 2024.
Conclusion
India’s entry into the top six nations for 6G patent filings signifies a strategic leap towards becoming a global leader in next-generation wireless technology. With continued investment in research, infrastructure, and international collaboration, India is poised to play a pivotal role in defining the future of telecommunications.
Trina Solar Leads Global Perovskite Solar Cell Patent Rankings
Trina Solar, a global leader in photovoltaic (PV) technology, has emerged at the forefront of perovskite solar cell innovation, boasting a significant portfolio of patents in this cutting-edge field. The company’s extensive research and development efforts have positioned it as a key player in advancing perovskite-based solar technologies.
Pioneering Perovskite Innovations
Since initiating research into perovskite and crystalline silicon tandem cell technology in 2014, Trina Solar has accumulated a substantial number of technological innovations. These advancements underscore the company’s commitment to enhancing solar cell efficiency and performance through novel materials and structures.
Robust Patent Portfolio
Trina Solar’s dedication to innovation is reflected in its impressive patent holdings. The company has applied for over 5,000 patents worldwide, with more than 3,000 granted, including over 500 patents specifically related to TOPCon (Tunnel Oxide Passivated Contact) cells and modules. This extensive patent portfolio not only safeguards Trina’s technological advancements but also reinforces its leadership in the solar industry.
Strategic Legal Actions
To protect its intellectual property, Trina Solar has actively pursued legal measures against entities infringing upon its patented technologies. A lawsuit was filed in the U.S. District Court of Delaware and a complaint with the U.S. International Trade Commission (ITC) against Canadian Solar, Inc., alleging infringement of its TOPCon technology patents. These actions underscore Trina’s commitment to defending its innovations and maintaining fair competition in the industry.
Global Impact and Future Outlook
Trina Solar’s advancements in perovskite solar cell technology have significant implications for the global renewable energy landscape. By pushing the boundaries of solar cell efficiency and performance, the company contributes to the broader adoption of clean energy solutions worldwide. As the demand for high-efficiency solar technologies continues to grow, Trina Solar’s pioneering work in perovskite solar cells positions it to play a pivotal role in shaping the future of sustainable energy.
*For more information on Trina Solar’s innovations and patent portfolio, visit www.trinasolar.com.*
IIIT-Bangalore Hosts Patent Workshop to Boost Academic Innovation
In a significant move to strengthen the intellectual property (IP) landscape within Karnataka’s academic institutions, the International Institute of Information Technology Bangalore (IIIT-B) organized a one-day workshop titled “Patent Proficiency for Academic Innovators.” The event, held under the New Age Innovation Network (NAIN) 2.0 program, aimed to equip students, faculty, and innovators with practical knowledge on innovation.
Empowering Academic Innovators
The workshop was conducted in collaboration with Startup Karnataka and the Department of IT, BT, Government of Karnataka. Distinguished speakers included Nithin Chakki, KAS, General Manager of the Karnataka Innovation and Technology Society (KITS); Cmd. Sridhar, Registrar of IIIT-B; Prakash Balekundri, CEO of Unique Patent Solutions. They emphasized the critical role of intellectual property rights (IPR) in translating academic research into market-ready solutions.
The sessions provided attendees with insights into identifying patentable ideas, navigating the patent filing process, and enhancing the quality of patent applications. Real-world case studies and expert guidance were integral to the workshop, offering participants a comprehensive understanding of the journey from research ideation to securing intellectual property.
Extending Reach to Tier-2 Institutions
As an anchor institute for the NAIN 2.0 program, IIIT-B extended the workshop’s benefits to several affiliated institutions, including Jain (Deemed-to-be University), Bapuji Institute of Engineering & Technology in Davangere, Malnad College of Engineering, Mangalore Institute of Technology and Engineering, and St. Philomena College in Puttur. This initiative reflects a growing commitment among Tier-2 city institutions to build robust IPR ecosystems and contribute to the state’s innovation goals.
Fostering a Culture of Innovation
Dr. Lakshmi Jagannathan stressed the importance of guiding these innovators in protecting their work, commercializing it, and contributing meaningfully to the economy. The workshop also focused on strengthening the capabilities of Technology Transfer Offices (TTOs) within institutions, emphasizing their role in bridging the gap between innovative ideas and IP protection.
About IIIT-Bangalore and Its Innovation Centre
The IIIT-B Innovation Centre serves as a dynamic hub for fostering innovation, entrepreneurship, and cutting-edge research. As a not-for-profit Section 8 company hosted by IIIT-Bangalore, the centre offers state-of-the-art incubation facilities, advanced labs, and access to expert mentorship. It supports projects across various domains, including artificial intelligence, data science, Internet of Things (IoT), and digital health. Having supported over 100 startups, the centre plays a pivotal role in nurturing emerging talent and driving technological advancements, positioning itself as a key enabler of innovation and collaboration in India’s tech ecosystem.
IIIT-Bangalore, Situated in the heart of Electronic City, Bangalore, it holds a prominent position in the academic landscape and is graded A+ by the National Assessment and Accreditation Council (NAAC).
The successful execution of the “Patent Proficiency for Academic Innovators” workshop marks a significant step forward in Karnataka’s vision to cultivate a knowledge-led innovation economy, ensuring that academic discoveries translate into impactful, real-world solutions.
CarbonScape Awarded EU Patent, Poised to Transform EV Battery Supply Chain with Sustainable Biographite
In a major milestone for sustainable technology, New Zealand-based clean-tech company CarbonScape has been officially granted a European Union patent for its innovative biographite production process. The development is expected to dramatically reshape the electric vehicle (EV) battery supply chain by offering an eco-friendly alternative to traditional graphite—a key material in lithium-ion batteries.
The Challenge with Traditional Graphite
Graphite plays a critical role in EV batteries as the primary material used in anodes. However, the global supply of graphite has long been fraught with environmental and geopolitical challenges. Synthetic graphite, commonly used in high-performance batteries, is energy-intensive and derived from petroleum coke, resulting in high carbon emissions. Natural graphite, often sourced through mining, raises concerns about ecological degradation and unsustainable extraction practices.
CarbonScape’s Breakthrough: Biographite
This novel material serves as a carbon-negative substitute for synthetic and mined graphite, aligning with global efforts to reduce the carbon footprint of EVs.
Unlike traditional graphite production methods that require extreme heat of up to 3,000°C, CarbonScape’s process operates at significantly lower temperatures, around 1,500°C. Most notably, the production of biographite can actually remove more carbon dioxide from the atmosphere than it emits, making it a potentially revolutionary contributor to climate change mitigation.
EU Patent Strengthens Global Reach
With the newly issued EU patent, CarbonScape secures exclusive rights to its biographite technology in one of the world’s largest EV markets. The patent provides legal and commercial leverage as the company accelerates its plans to scale up production in Europe and beyond.
“It not only validates the uniqueness of our technology but also paves the way for localizing battery supply chains with a sustainable, homegrown solution.”
Localizing and Decarbonizing the Battery Supply Chain
One of CarbonScape’s major strategic advantages lies in its ability to decentralize production. By building smaller, localized plants near battery manufacturing hubs, the company can reduce transportation emissions and improve supply chain resilience.
According to internal estimates, producing biographite could avoid up to 30 tons of CO₂ emissions for every ton manufactured, compared to traditional graphite. As countries strive to meet ambitious net-zero goals, this kind of innovation could become indispensable.
Global Expansion and Strategic Partnerships
CarbonScape has already begun setting the groundwork for expansion. Commercial-scale production is projected to begin by 2029, with a goal of meeting at least 50% of the projected graphite demand for EV and grid-scale batteries by 2030.
These partnerships are expected to provide both financial support and industrial know-how needed to accelerate commercialization.
Sustainability at the Forefront
The move to biographite underscores a larger trend in the EV industry toward greener and more ethical sourcing of battery materials. As regulatory bodies in the EU and elsewhere implement stricter sustainability requirements, CarbonScape’s technology positions itself as a forward-looking solution ready for rapid adoption.
“With this patent, we’re not just protecting a technology—we’re setting a new standard for what sustainable battery materials should look like,” Williams emphasized.
Outlook
As the automotive world shifts gears toward zero-emission mobility, innovations like biographite could be the missing link in creating truly green batteries—from the source to the road.
If scaled effectively, CarbonScape’s approach could offer the EV industry a blueprint for sustainable growth—one that is not only more environmentally responsible but also more resilient to supply chain disruptions.
Vedanta Aluminium Secures Patent for Breakthrough Graphite Recovery Technology on National Technology Day 2025
In a landmark achievement announced on National Technology Day 2025, Vedanta Aluminium, India’s largest aluminium producer, revealed that it has been granted a patent for a pioneering technology that enables the recovery of graphite with over 99% purity from aluminium production waste. This breakthrough positions the company—and the country—at the forefront of sustainable manufacturing and critical mineral independence.
Turning Waste into Strategic Wealth
Reflecting this year’s theme, ‘YANTRA – Yugantar for Advancing New Technology, Research & Acceleration’, Vedanta’s patented innovation transforms industrial waste into a high-value resource, exemplifying the ethos of circular economy and deep-tech advancement.
The technology recovers battery-grade graphite from two hazardous waste streams in aluminium production—Spent Pot Lining (SPL) and Shot Blast Dust. These materials, previously considered non-recoverable and environmentally challenging, are now being repurposed into a strategic asset critical for India’s clean energy future.
A Critical Boost for India’s Mineral Security
The graphite recovered through this technology exhibits exceptional electrical conductivity and robust structural properties, making it ideally suited for use in lithium-ion batteries. Its atomic structure supports efficient lithiation and de-lithiation cycles, which are essential for energy storage systems in electric vehicles, renewable energy integration, and consumer electronics.
The new technology has the potential to significantly reduce this dependency. As one of the top three graphite importers in the Asia-Pacific region—alongside South Korea and Japan—India now has an opportunity to become self-reliant in this critical mineral segment.
Driving Sustainable Innovation
The achievement is emblematic of a larger shift in Indian industry toward innovation-led sustainability. By unlocking new value from what was once waste, Vedanta Aluminium is setting a precedent for responsible industrial practices that support both economic growth and environmental stewardship.
The company’s graphite recovery initiative also contributes to global climate goals by enabling cleaner energy technologies while reducing the environmental burden of industrial waste. It represents a scalable, replicable model for circular economy integration in heavy industry.
Looking Ahead
As India accelerates its transition to a green and self-reliant economy, innovations like Vedanta’s graphite recovery technology will play a critical role in bridging the gap between sustainability and industrial competitiveness. The patent marks not just a technological breakthrough, but a strategic leap toward a cleaner, more resilient future for India.
Indian Pharma Stocks Tumble Amid Trump’s Drug Price Cut Order: Industry Braces for Patent Clampdown
In a significant development that sent shockwaves across global pharmaceutical markets, U.S. President Donald Trump signed an executive order aimed at drastically reducing prescription drug prices in the United States. The move has triggered a sharp decline in Indian pharmaceutical stocks, raising concerns about the future of generic drug exports and the potential tightening of global patent regimes.
Trump Pushes for Global Price Parity
President Trump’s executive order, signed on Monday, mandates that U.S. drug prices should align with the lowest prices paid by other developed nations. Under the proposed “Most Favoured Nation” policy, the U.S. would no longer pay more for prescription medicines than any other country. The administration has given pharmaceutical companies 30 days to propose pricing solutions. Should they fail to deliver “significant progress” within six months, further government intervention is expected.
In a social media post, Trump argued that American consumers were unfairly burdened by high drug prices, noting that medicines manufactured in the same facilities are sold for significantly less in other countries. He emphasized that the United States bears a disproportionate share of global research and development costs, indirectly subsidizing affordable drugs for the rest of the world.
Indian Pharma Sector Reacts
The announcement caused immediate ripples in Indian stock markets. Shares of major pharmaceutical firms such as Sun Pharma plunged nearly 7% during early trading, while others including Lupin, Aurobindo Pharma, Divi’s Laboratories, and Glenmark Pharma also experienced a selloff.
Although Trump’s pricing directive primarily targets patented and branded drugs, experts warn of indirect consequences for India’s generic drug industry, which is heavily reliant on the U.S. market for exports.
“The concern lies in the potential policy response from multinational pharma companies,” said P.V. Appaji, former Director General of the Pharmaceuticals Export Promotion Council (Pharmexcil).
Threat of Patent Barriers Looms
Industry analysts believe that global drugmakers may respond to the price caps by tightening intellectual property regulations to prolong their market exclusivity and recover R&D investments. Potential measures include data exclusivity, automatic patent term extensions, patent linkage mechanisms, broader patentability criteria, and evergreening tactics.
Such practices, if adopted widely, could delay the entry of generic drugs into global markets and restrict the availability of off-patent drugs for Indian manufacturers. “These moves threaten to shrink the pipeline of medicines going off-patent, directly impacting India’s generic export prospects,” warned Ravi Uday Bhaskar, another former Pharmexcil chief.
India’s Stance on Patent Flexibilities
India has historically resisted stringent patent norms in trade negotiations, advocating for access to affordable medicines as a public health priority. The country does not recognize data exclusivity and maintains that regulatory authorities can rely on existing clinical trial data to approve generics. It also rejects patent linkage, preventing unnecessary legal hurdles that could delay the launch of affordable versions.
“India blocks evergreening by disallowing patents for minor modifications to existing drugs,” said Ajay Srivastava, founder of the Global Trade Research Initiative (GTRI).
However, if global pharmaceutical giants succeed in influencing trade agreements to include such provisions, Indian generic drug manufacturers may face significant challenges. The development and export of specialty generics—high-value, complex generics—could particularly be affected.
The Road Ahead
While the immediate impact of Trump’s executive order may be limited to branded drugs, the broader implications could be far-reaching for India’s pharmaceutical industry. Any moves to fortify global patent laws or extend exclusivity periods could undermine India’s position as the “pharmacy of the world” and disrupt access to affordable medications in many countries.
As the U.S. pushes forward with its aggressive drug pricing reforms, industry stakeholders and policymakers in India will need to closely monitor international negotiations and advocate for a balanced approach that safeguards innovation without compromising global health access.